

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

Editorial Office: International Institute of Anticancer Research,
1st km Kapandritiou - Kalamou Rd., Kapandriti, POB 22, Attiki
19014, Greece. Fax: 0030-22950-53389; Tel: 0030-22950-52945
e-mail: journals@iiar-anticancer.org

Dear Sir/Madam:

Enclosed are the galley proofs of your article for ANTICANCER RESEARCH.

We would like to call your attention to the following:

1. Please read thoroughly, correct, and return the proofs to the Editorial Office **within 24 hours**.
2. Proofs should be returned preferably **by e-mail** or **fax**. Delays in the return of these proofs will necessitate the publication of your paper in a later issue of the journal.
3. Please read the entire manuscript carefully to verify that no changes in meaning have been introduced into the text through language improvements or editorial corrections.
4. Corrections should be limited to typographical errors.
5. Should you require reprints, PDF files, issues or special author rate subscriptions, please fill the attached reprint order form.
6. Should you require information about your article (publication date, volume, page numbers, etc) please call: +30-22950-52945 or send an e-mail to journals@iiar-anticancer.org.
7. Please provide your complete address (not P.O.B.), telephone and fax numbers for the delivery of reprints and issues.
8. Please feel free to contact us with any queries that you may have (Tel./Fax: +30-22950-53389 or +30-22950-52945, e-mail: journals@iiar-anticancer.org).

Thank you for taking the time to study these guidelines.
I greatly appreciate your cooperation and your contribution to this journal.

Yours sincerely,



J.G. Delinassios
Managing Editor

Enclosures

Significant Association of Caveolin-1 (CAVI) Genotypes with Breast Cancer in Taiwan

LIANG-CHIH LIU^{1,3*}, CHEN-HSIEN SU^{1,3*}, HWEI-CHUNG WANG³, CHIA-WEN TSAI^{3,4},
 WEN-SHIN CHANG^{3,4}, CHIEN-YI HO², CHAO-I WU³, FENG-JING LI³,
 CHIH-HSUEH LIN², HSIEN-YUAN LANE³ and DA-TIAN BAU^{3,4,5}

Departments of ¹Surgery and ²Family Medicine, and ³Terry Fox Cancer Research Laboratory,
 China Medical University Hospital, Taichung, Taiwan, R.O.C.;
 Institutions of ⁴Basic Medical Sciences, and ⁵Clinical Medical Sciences,
 China Medical University, Taichung, Taiwan, R.O.C.

Abstract. *Aim:* Japanese and American groups reported that single nucleotide variation of caveolin-1 gene (CAVI) plays an important role in breast cancer risk. The aim of this study was to evaluate the association of six polymorphic genotypes of CAVI, which is reported to be overexpressed in tumors, with breast cancer within a Taiwanese population. *Materials and Methods:* A total of 1232 patients with breast cancer and equal number of healthy controls in central Taiwan were genotyped via polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) and six polymorphic variants of CAVI were analyzed for their association with breast cancer susceptibility. *Results:* The distribution of genotypes of CAVI G14713A and T29107A were significantly different between breast cancer and control groups ($p=5.6 \times 10^{-5}$ and 1.9×10^{-4} , respectively), while those for CAVI C239A, G21985A, T28608A and G32124A were not significant ($p>0.05$). The percentages of AG genotype of G14713A and TT genotype of T29107A are higher in the cancer group than in the control group. The two single nucleotide polymorphisms were chosen for haplotype analysis and the data showed that compared with GG/TT haplotype of CAVI G14713A/T29107A, the GG/AT and GG/AA groups have a lower risk of breast cancer (odds ratio, OR=0.69, 95% confidence interval, CI=0.57-0.92). On the contrary, the AG/TT haplotype confers a higher risk of breast cancer (OR=1.50, 95% CI=1.14-2.12). *Conclusion:* Our results provide evidence for CAVI genotypes being

involved in predisposition to breast cancer. The association of the potential risk haplotype agrees well with a role of CAVI genotype in breast cancer risk and the association with tumor progression needs further investigation.

Breast cancer is about twice as common in the first-degree relatives of women with the disease as in the general population, consistent with variation in genetic susceptibility to the disease (1). Inherited mutations in *BRCA1* and *BRCA2* genes lead to a high risk of breast and other types of cancer, however, the majority of many familial cases do not segregate mutations in the two genes (2). This observation has led to the concept that breast cancer susceptibility is largely 'polygenic', that is, susceptibility is conferred by multiple loci, each with a small effect on breast cancer risk (3).

Multiple independent lines of experimental evidence suggest that the gene for caveolin1 (*CAVI*) functions as a mammary gland tumor suppressor gene (4, 5). Firstly, *CAVI* mRNA and protein levels are down-regulated in various cancer cell lines, including in oncogene-transformed NIH 3T3 cells, in many human and mouse breast cancer cell lines, in primary human mammary gland tumors, and in transgenic breast cancer mouse cells (6-9). Secondly, *CAVI* re-expression in breast cancer cell lines inhibits anchorage-dependent growth in soft agar and reduces their invasive potential (8, 10). Finally, *CAVI* expression also reduces the migratory and invasive potential of MTLn3 cells, a metastatic mammary carcinoma line, by preventing epidermal growth factor (EGF)-induced lamellipodia formation and reducing cell migration (11). In the human genome, *CAVI* gene consists of three exons and is located at 7q31.1. *CAVI* is the major structural and functional protein component of caveolae, which plays an important role in many signaling pathways, molecular transport, and cellular proliferation and differentiation. The specific functions of the *CAVI* protein are highly cell- and context-dependent (12). The genomic association of *CAVI* with all types of cancer is

*These Authors contributed equally to this study.

Correspondence to: Da-Tian Bau, Terry Fox Cancer Research Laboratory, China Medical University Hospital, 2 Yuh-Der Road, Taichung, 404 Taiwan, R.O.C. Tel: +886 422052121 Ext. 1523, e-mail: datian@mail.cmuh.org.tw; artbau2@gmail.com.tw

Key Words:

Table I. Characteristics among breast cancer patients and controls.

Characteristic	Controls (n=1232)			Patients (n=1232)			P-value
	n	%	Mean (SD)	n	%	Mean (SD)	
Age at onset (years)							
<40	359	29.1%		362	29.4%		0.89 ^a
40-55	558	45.3%		547	44.4%		
>55	315	25.6%		323	26.2%		
Age at menarche (years)			12.4 (0.7)			12.1 (0.6)	0.79 ^b
Age at first birth of child (years)			29.4 (1.2)			29.8 (1.4)	0.63 ^b
Age at menopause (years)			48.8 (1.8)			49.3 (2.0)	0.59 ^b
Site							
Unilateral				1198	97.2%		
Bilateral				34	2.8%		
Family history							
First degree (Mother, sister and daughter)				55	4.5%		
Second degree				6	0.5%		
No history				1171	95%		
Habit							
Cigarette smokers	86	7.0%		170	13.8%		<0.0001 ^a
Alcohol drinkers	91	7.4%		162	13.1%		<0.0001 ^a

Statistical results based on ^aChi-square and ^bunpaired Student's *t*-test.

not well understood and the analyzes are often focused on the genetic mutations not polymorphisms. In 2006, a study reported that some mutations of *CAVI* were associated with breast cancer risk (13). The above evidence pointing to the role of *CAVI* in carcinogenesis led us to study whether different alleles of this gene are associated with breast cancer. Thus, the aims of the current study were to determine the genotypic frequency of six polymorphisms of the *CAVI* gene at C239A (rs1997623), G14713A (rs3807987), G21985A (12672038), T28608A (rs3757733), T29107A (rs7804372), and G32124A (rs3807992), and their association with breast cancer susceptibility.

Materials and Methods

Study population and sample collection. The study population consisted of 1232 breast cancer patients and 1232 age-matched cancer-free control volunteers. The patients diagnosed with breast cancer were recruited at the outpatient clinics of general surgery between 2004 and 2008 at the China Medical University Hospital, Taichung, Taiwan, Republic of China. The clinical characteristics of the patients including their histological details were all graded and defined by expert surgeons (Dr. Wang, Liu and Su). All patients voluntarily participated, completed a self-administered questionnaire and provided peripheral blood samples. The same number of age-matched non-breast cancer, healthy volunteers as controls were selected after initial random sampling from the Health Examination Cohort of the hospital. The exclusion criteria for the control group included previous malignancy, metastasized cancer from other or unknown origin, and any familial or genetic diseases. Both groups completed a short questionnaire which included habits.

Genotyping conditions. Genomic DNA was prepared from peripheral blood leucocytes using a QIAamp Blood Mini Kit (Blossom, Taipei, Taiwan) and further processed according to our previous methods (14-20). Briefly, the following primers were used for *CAVI* genotyping: for C239A (rs1997623), 5'-GTGTCCGTTCTGCTATCTG-3' and 5'-GCCAAGATGCAGAAGGAG TT-3'; for G14713A (rs3807987), 5'-CCTTCCAGTAAGCAAGCTGT-3' and 5'-CCTCTCAATCTTGCCATAGT-3'; for G21985A (12672038), 5'-GGTGTGCAAGGCTATGCT-3' and 5'-CCAGACACTCAGAA TGTGAC-3'; for T28608A (rs3757733), 5'-GCTCAACCTCATCTG AGGCA-3' and 5'-GGCCTATTGTTGAGTGGATG-3'; for T29107A (rs7804372), 5'-GCCTGAATTGCAATCCTGTG-3' and 5'-ACGGTGTGAACACGGACATT-3'; and for G32124A (rs3807992), 5'-GGTGTCTTGCAGTTGAATG-3' and 5'-ACGGAGCTACTCAG TGCCAA-3'. The following cycling conditions were used: one cycle at 94°C for 5 min; 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s; and a final extension at 72°C for 10 min. The PCR products were studied after digestion with *AvrII*, *BfaI*, *HaeIII*, *Tsp509I*, *Sau3AI* and *NlaIII*, restriction enzymes for *CAVI* C239A (cut from 485 bp C type into 170+315 bp T type), G14713A (cut from 268 bp A type into 66+202 bp G type), G21985A (cut from 251+43 bp A type into 153+98+43 bp G type), T28608A (cut from 298 bp T type into 100+198 bp A type), T29107A (cut from 336 bp A type into 172+164 bp T type), and G32124A (cut from 213+142+67 bp A type into 142+118+95+67 bp T type), respectively.

Statistical analyses. Only those matches with all the single nucleotide polymorphism data (case/control=1232/1232) were selected for the final analysis. To ensure that the controls used were representative of the general population and to exclude the possibility of genotyping error, the deviation of the genotype frequencies of *CAVI* single nucleotide polymorphism in the controls

Table II. Distribution of *CAVI* genotypes among breast cancer patients and controls.

Genotype	Controls		Patients		<i>P</i> -value ^a
	n	%	n	%	
239A rs1997623					0.3486
CC	1190	96.6%	1179	95.6%	
AC	39	3.2%	52	4.2%	
AA	3	0.2%	2	0.2%	
G14713A rs3807987					0.000056
GG	801	65.0%	704	57.1%	
AG	311	25.2%	409	33.2%	
AA	120	9.7%	119	9.7%	
G21985A rs12672038					0.2442
GG	742	60.2%	718	58.3%	
AG	401	32.5%	403	32.7%	
AA	89	7.3%	111	9.0%	
T28608A rs3757733					0.9522
TT	718	58.3%	713	58.4%	
AT	409	33.2%	401	32.8%	
AA	105	8.5%	108	8.8%	
T29107A rs7804372					0.00019
TT	649	52.7%	745	60.5%	
AT	472	38.3%	410	33.2%	
AA	111	9.0%	77	6.3%	
G32124A rs3807992					0.4962
GG	604	49.0%	588	47.7%	
AG	493	40.0%	520	42.2%	
AA	135	11.0%	124	10.1%	

^a*P* based on Chi-square test.

from those expected under the Hardy-Weinberg equilibrium was assessed using the goodness-of-fit test. Pearson's chi-square test or Fisher's exact test (when the expected number in any cell was less than five) was used to compare the distribution of the *CAVI* genotypes between cases and controls. Cancer risk associated with the genotypes was estimated as odds ratio (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression. The data was recognized as significant when the statistical *p*-value was less than 0.05. To evaluate effect modification by smoking, stratified analyses were conducted for chosen SNPs to compare the association across exposure categories of smoking status (never-smokers and smokers). All statistical tests were performed using SAS, Version 9.1.3 (SAS Institute Inc., Cary, NC, USA) on two-sided probabilities.

Results

The frequency distributions of selected characteristics of 1232 breast cancer patients and 1232 non-cancer controls are shown in Table I. These characteristics of patients and controls were all well matched. None of the differences between groups were statistically significant (*p*>0.05) (Table I). As for the individual behaviors, cigarette smoking and alcoholism were significantly more frequent in the breast cancer group in this population (*p*<0.05) (Table I).

Table III. Distribution of *CAVI* alleles among breast cancer patients and controls.

Allele	Controls		Patients		<i>P</i> -value ^a
	n	%	n	%	
C239A rs1997623					0.2705
Allele C	2419	98.2%	2410	97.7%	
Allele A	45	1.8%	56	2.3%	
G14713A rs3807987					0.0014
Allele G	1913	77.6%	1817	73.7%	
Allele A	551	22.4%	647	26.2%	
G21985A rs12672038					0.1273
Allele G	1885	76.5%	1839	74.6%	
Allele A	579	23.5%	625	25.4%	
T28608A rs3757733					0.9205
Allele T	1845	74.9%	1827	74.8%	
Allele A	619	25.1%	617	25.2%	
T29107A rs7804372					0.00022
Allele T	1770	71.8%	1900	77.1%	
Allele A	694	28.2%	564	22.9%	
G32124A rs3807992					0.8777
Allele G	1701	69.0%	1696	68.8%	
Allele A	763	31.0%	768	31.2%	

^a*P* based on Chi-square test.

The frequencies of the genotypes for *CAVI* C239A (rs1997623), G14713A (rs3807987), G21985A (12672038), T28608A (rs3757733), T29107A (rs7804372), and G32124A (rs3807992) in controls and breast cancer patients are summarized in Table II. The distribution of genotypes of *CAVI* G14713A and T29107A were significantly different between breast cancer and control groups (*p*=0.000056 and 0.00019, respectively) with a higher proportion of AG carriers and TT carriers, respectively, in the breast cancer group. Differences for *CAVI* C239A, G21985A, T28608A and G32124A were not significant (*p*>0.05) (Table II). We also performed allelic frequency analysis, and the frequencies of the alleles for *CAVI* C239A, G14713A, G21985A, T28608A, T29107A and G32124A in controls and breast cancer cases are shown in Table III. The two SNPs of *CAVI* found to be associated with breast cancer risk in Table II, G14713A and T29107A, were again found to be associated with higher breast cancer susceptibility, with greater frequency of the A allele and T allele, respectively, in their allele in the breast cancer group (Table III; *p*=0.00014 and 0.00022, respectively). As for the other four SNPs, the distributions of their allele frequencies were not significantly different in controls and breast cancer patients (Table III).

Considering potential interactions between the two significant SNPs of the *CAVI* gene and breast cancer susceptibility, the risk of breast cancer as related to haplotypic distributions of *CAVI* G14713A and T29107A were further analyzed (Table IV). Compared with the GG/TT haplotype of

Table IV. Distribution of *CAVI* G14713A/T29107A haplotypes among breast cancer patients and controls.

G14713A/ T29107A haplotype	Controls		Patients		Odds ratio	Adjusted odds ratio	P-value ^b
	n	%	n	%	(95% CI)	(95% CI) ^a	
GG/TT	422	34.3%	425	34.5%	1.00 (Reference)	1.00 (Reference)	
GG/AT or GG/AA	379	30.8%	279	22.6%	0.73 (0.60-0.90)	0.69 (0.57-0.92)	0.0025
AG/TT	164	13.3%	247	20.0%	1.50 (1.18-1.90)	1.48 (1.14-2.12)	0.0011
AG/AT or AG/AA	147	11.9%	162	13.1%	1.09 (0.84-1.42)	1.08 (0.85-1.44)	0.5069
AA/TT	63	5.1%	72	5.8%	1.13 (0.79-1.63)	1.10 (0.76-1.65)	0.5174
AA/AT or AA/AA	57	4.6%	47	3.8%	0.82 (0.54-1.23)	0.86 (0.59-1.24)	0.3513

95% CI, 95% confidence interval. ^aAdjusted for age, smoking, and alcohol drinking behaviors. ^bBased on Fisher's exact two-tailed test.

CAVI G14713A/T29107A, the GG/AT and GG/AA groups have a lower risk of breast cancer (OR=0.69, 95% CI=0.57-0.92). On the contrary, the AG/TT haplotype conferred a higher risk of breast cancer (OR=1.50, 95% CI=1.14-2.12). After adjusting for age, smoking and alcohol drinking behaviors, these differences remained significant. Other combinations of AG/AT or AG/AA, AA/TT, and AA/AT or AA/AA did not confer significantly altered cancer risk compared to the wild-type GG/TT haplotype (Table IV). The results showed that individuals with the heterozygous AG genotype, but not homozygous AA genotype, of *CAVI* G14713A were at higher risk of breast cancer. As for *CAVI* T29107A, those with TT genotype were at higher breast cancer risk.

Discussion

In 2001, a Japanese group reported that up to 16% of breast cancer samples harbored a P132L mutation in the *CAVI* gene (21). Furthermore, in the population of the USA, it was reported that the *CAVI* P132L mutation is present in about 19% of estrogen receptor α (ER α)-positive breast cancer cases but not in ER α -negative breast cancer cases. (13). All the data suggested that the single nucleotide variations played an important role in breast carcinogenesis. Thus, we aimed at investigating the association of *CAVI* polymorphism with breast cancer.

In this study, the genotypes of 1232 breast cancer patients and the same number of age-matched cancer-free controls were examined. We found that the genotypes of *CAVI* single nucleotide polymorphisms, G14713A and T29107A were differentially distributed between the breast cancer and healthy control groups (Table II). In addition, the allelic frequencies of the two SNPs were also differentially distributed between the two groups (Table III). The results showed that the A allele of G14713A and T allele of T29107A were both risk factors for breast cancer susceptibility. Furthermore, the combination haplotypes of *CAVI* G14713A and T29107A were also examined (Table IV). The results suggest that individuals with the GG/AT or

GG/AA G14713A/T29107A haplotype were at lower risk of breast cancer, and those with AG/TT haplotype were at higher risk, compared with the GG/TT haplotype (Table IV). It is interesting to note that those with the AA/TT haplotype did not have the highest odds ratio of breast cancer.

The sample size and similar trends of significant data after age and behavior adjustments (Table IV) strengthen the accuracy and reliability of our findings. In addition, the frequencies of *CAVI* polymorphic variant alleles were similar to those reported in the NCBI website for other Asian population studies. For instance, the minor A allele frequency of *CAVI* G14713A was 22.4% in our control group, close to those of 16.7% for Beijing and 22.2% for Tokyo populations in NCBI, which strongly suggests no selection bias for participant enrolments in terms of genotypes.

In conclusion, this is the first report to provide evidence for *CAVI* single nucleotide polymorphisms G14713A and T29107A, but not C239A, G21985A, T28608A, or G32124A, being associated with breast cancer risk. The A allele of *CAVI* G14713A and T allele of *CAVI* T29107A might become potential biomarkers for the early screening detection and prediction of breast cancer and integrative cancer therapy.

Acknowledgements

We thank Judy Wang, Tzu-Shin Weng and the Tissue Bank at the China Medical University for their technical assistance. This study was supported by research grants from the Terry Fox Cancer Research Foundation, and China Medical University and Hospital (DMR-100-179).

References

- 1 Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* 358: 1389-1399, 2001.
- 2 Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski , Gronwald J, Gorski B, Tulinius

- H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG and Easton DF: Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 72: 1117-1130, 2003.
- 3 Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF and Ponder BA: Polygenic susceptibility to breast cancer and implications for prevention. *Nat Genet* 31: 33-36, 2002.
 - 4 Williams TM and Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. *Am J Physiol Cell Physiol* 288: C494-506, 2005.
 - 5 Bouras T, Lisanti MP and Pestell RG: Caveolin-1 in breast cancer. *Cancer Biol Ther* 3: 931-941, 2004.
 - 6 Koleske AJ, Baltimore D and Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. *Proc Natl Acad Sci USA* 92: 1381-1385, 1995.
 - 7 Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG and Lisanti MP: Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression *in vitro* and *in vivo*. Implications for human breast cancer. *J Biol Chem* 273: 20448-20455, 1998.
 - 8 Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. *Oncogene* 16: 1391-1397, 1998.
 - 9 Park J and Kim J. Evaluation of iQ200 automated urine microscopy analyzer. *Korean J Lab Med* 28: 267-273, 2008.
 - 10 Fiucci G, Ravid D, Reich R and Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. *Oncogene* 21: 2365-2375, 2002.
 - 11 Zhang W, Razani B, Altschuler Y, Bouzazhah B, Mostov KE, Pestell RG and Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. *J Biol Chem* 275: 20717-20725, 2000.
 - 12 Li WP, Liu P, Pilcher BK and Anderson RG: Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. *J Cell Sci* 114: 1397-1408, 2001.
 - 13 Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA and Lisanti MP: Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. *Am J Pathol* 168: 1998-2013, 2006.
 - 14 Wang HC, Chang WS, Tsai RY, Tsai CW, Liu LC, Su CH, Cheng HN, Tsou YA, Sun SS, Lin CC and Bau DT: Association between ataxia telangiectasia mutated gene polymorphisms and breast cancer in Taiwanese females. *Anticancer Res* 30: 5217-5221, 2010.
 - 15 Wang HC, Liu CS, Chiu CF, Chiang SY, Wang CH, Wang RF, Lin CC, Tsai RY and Bau DT: Significant association of DNA repair gene *Ku80* genotypes with breast cancer susceptibility in Taiwan. *Anticancer Res* 29: 5251-5254, 2009.
 - 16 Wang HC, Chiu CF, Tsai RY, Kuo YS, Chen HS, Wang RF, Tsai CW, Chang CH, Lin CC and Bau DT: Association of genetic polymorphisms of *EXO1* gene with risk of breast cancer in Taiwan. *Anticancer Res* 29: 3897-3901, 2009.
 - 17 Chiu CF, Wang HC, Wang CH, Wang CL, Lin CC, Shen CY, Chiang SY and Bau DT: A new single nucleotide polymorphism in *XRCC4* gene is associated with breast cancer susceptibility in Taiwanese patients. *Anticancer Res* 28: 267-270, 2008.
 - 18 Liu CJ, Hsia TC, Wang RF, Tsai CW, Chu CC, Hang LW, Wang CH, Lee HZ, Tsai RY and Bau DT: Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. *Anticancer Res* 30: 1195-1199, 2010.
 - 19 Liu CJ, Hsia TC, Tsai RY, Sun SS, Wang CH, Lin CC, Tsai CW, Huang CY, Hsu CM and Bau DT: The joint effect of *hOGG1* single nucleotide polymorphism and smoking habit on lung cancer in Taiwan. *Anticancer Res* 30: 4141-4145, 2010.
 - 20 Wu HC, Chang CH, Tsai RY, Lin CH, Wang RF, Tsai CW, Chen KB, Yao CH, Chiu CF, Bau DT and Lin CC: Significant association of methylenetetrahydrofolate reductase single nucleotide polymorphisms with prostate cancer susceptibility in Taiwan. *Anticancer Res* 30: 3573-3577, 2010.
 - 21 Hayashi, K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T and Hamaguchi M: Invasion activating caveolin-1 mutation in human scirrhous breast cancers. *Cancer Res* 61: 2361-2364, 2001.

Received June 20, 2011

Revised August 26, 2011

Accepted August 29, 2011

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

August 29, 2011

Dr. Da-Tian Bau

Re: Your manuscript No. **13610-L** entitled «**Significant Association of Caveolin-1...**»

Dear Dr

Referring to your above manuscript for publication in AR, please allow us to use this form letter in reply:

1. *Referee's recommendations:*

- Urgent to be published immediately.
- Accepted in the presented form.
- Accepted with minor changes.
- Accepted with grammatical or language corrections.
- Remarks: **Please provide Key words**

2. *Excess page charges.*

- Your article has approx. **5** printed pages and is in excess of the allotted number by approx. **1** printed pages. The charges are EURO € **210** per excess page, totalling EURO € **105 (-50% Discount)**
We ask you to confirm acceptance of these charges.
- Your article includes pages with color figures. The charges are EURO € per color page, totalling EURO €
- Our invoice will be sent by e-mail to the corresponding author.

3. Your article will appear in Volume **31**, Issue No. **10, 2011**

4. Please order your reprints now. This will facilitate our prompt planning of future issues and rapid publication of your article. Reprints will be delivered by air mail within one month from publication.

We would appreciate your prompt reply.

With many thanks,

Yours sincerely,



J.G. Delinassios

Managing Editor

EDITORIAL OFFICE: INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH
1st km Kapandritiou - Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel.: 0030-22950-52945;
Tel & Fax:0030-22950-53389; e-mail: journals@iiar-anticancer.org

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Editorial Office: International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece
Fax: +30-22950-53389; Tel: +30-22950-52945; e-mail: journals@iiar-anticancer.org

Please type or print the requested information on the reprint order form and return it to the Editorial Office by fax or e-mail.

Fees for reprints, PDF file, or online open access must be paid for in advance.

If your paper is subject to charges for excess pages or color plates, please add these charges to the payment for reprints. The reprints are not to be sold.

PRICE LIST FOR REPRINTS WITHOUT COVER

Page length	Online Open Access Fee (Euro)	PDF File Fee (Euro)	Number of copies requested (prices are in Euro)									
			100	200	300	400	500	1000	1500	2000	3000	5000
1-4pp	400	167	335	387	438	503	554	851	1135	1470	2038	3225
5-8	600	219	438	503	580	645	722	1083	1445	1832	2554	4012
9-12	700	277	554	619	709	787	877	1341	1780	2219	3096	4824
13-16	800	354	709	787	890	993	1096	1625	2141	2657	3676	5715
17-20	900	419	838	929	1032	1148	1277	1883	2451	3044	4244	6527

For reprints with cover: Please add EURO 140.00 per 100 copies.

Postage: Please add 5% on the above prices.

Reprint Order Form

Of my paper No. **13610-L** comprising **5** printed pages, entitled «**Significant Association of Caveolin-1...**» accepted for publication in ANTICANCER RESEARCH Vol. **31** No. **10**

- I require a total of _____ copies at EURO:
- I do not require reprints.
- Please send me a PDF file of the article at EURO:
- Please provide Online Open Access of the article at the IIAR website immediately upon publication at EURO:
- Please send me a copy of this issue containing my paper at EURO 45.00.
- Please enter my personal subscription to ANTICANCER RESEARCH at the special Author's price of EURO 417.00 (print or online); EURO 500.00 (print & online) (Year: 2011).
- A check for the above amounts payable to J.G. Delinassios, Executive Publisher of Anticancer Research Journal, is enclosed.
- Please send an invoice to:

For EC countries: Please give your VAT number:

City and Date:

Exact postal address:

Tel:

Fax:

Signature: